

- doi.org/10.1016/j.japh.2020.01.004.
32. Buffington, D.E., A. Lozicki, T. Alfieri, et al. "Understanding Factors That Contribute to the Disposal of Unused Opioid Medication." *Journal of Pain Research*, Vol. 12 (February 2019): 725–732. <https://doi.org/10.2147/jpr.s171742>.
33. Walmart. "Stewardship." <https://corporate.walmart.com/stewardship>. Accessed October 31, 2021.
34. Rite Aid. "Rite Aid Makes Free Opioid Disposal Solution Available At More Than 2,500 Pharmacies Nationwide." <https://www.businesswire.com/news/home/20180521005532/en/>. Accessed October 31, 2021.
35. CVS. "CVS Pharmacy to Offer Safe Medication Disposal Chain-Wide in 2020." <https://cvshealth.com/news-and-insights/press-releases/cvs-pharmacy-to-offer-safe-medication-disposal-chain-wide-in-2020>. Accessed November 1, 2021.
36. Walgreens. "Safe Medication Disposal—Dispose of Unused Medication." <https://www.walgreens.com/topic/pharmacy/safe-medication-disposal.jsp>. Accessed November 1, 2021.
37. Kroger. "National Drug Take-back Day" <https://www.kroger.com/health/pharmacy/prescriptions/takeback>. Accessed November 3, 2021.
38. Drug Take Back, Consolidated Laws of New York Chapter 45 Article 2–B, available at <https://www.nysenate.gov/legislation/laws/PBH/A2-B>.
39. Drug Take-Back Program, Revised Code of Washington 69.48, available at <https://app.leg.wa.gov/rcw/default.aspx?cite=69.48>.
40. Pharmaceutical and Sharps Waste Stewardship Program, California Code of Regulations Title 14, Chapter 11, Div. 7, Art. 4, available at [https://govt.westlaw.com/calregs/Browse/Home/Caifornia/CaliforniaCodeofRegulations?guid=I3A11525A8CDD4A6E87920B BB389851C4&originationContext=documenttoc&transitionType=Default&contextData=\(sc.Default\)](https://govt.westlaw.com/calregs/Browse/Home/Caifornia/CaliforniaCodeofRegulations?guid=I3A11525A8CDD4A6E87920B BB389851C4&originationContext=documenttoc&transitionType=Default&contextData=(sc.Default)).
41. Hwang, C.S., E.M. Kang, Y. Ding, et al. "Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003–2014." *JAMA Network Open*, Vol. 1(2) (June 2018): e180216. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2682877>.
42. Kennedy-Hendricks, A., A. Gielen, E. McDonald, et al. "Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults." *JAMA Internal Medicine*, Vol. 176(7) (July 2016): 1027–1029. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2527388>.
43. Neill, L.A., H.S. Kim, K.A. Cameron, et al. "Who Is Keeping Their Unused Opioids and Why?" *Pain Medicine*, Vol. 21(1) (January 2020): 84–91. <https://academic.oup.com/painmedicine/article/21/1/84/5418890>.
44. * FDA. "Safe Opioid Disposal—Remove the Risk Outreach Toolkit." [*medicines/safe-opioid-disposal-remove-risk-outreach-toolkit*. Accessed November 23, 2021.](https://www.fda.gov/drugs/safe-disposal-</p>
</div>
<div data-bbox=)

Dated: April 13, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022–08372 Filed 4–20–22; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; Summer Research Education R25 and DSR Member Conflict SEP.

Date: June 17, 2022.

Time: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Dental & Craniofacial Research, 6701 Democracy Blvd., Bethesda, MD 20817 (Virtual Meeting).

Contact Person: Aiwu Cheng, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities National Institute of Dental & Craniofacial Research, National Institutes of Health, 6701 Democracy Blvd., Bethesda, MD 20892, Aiwu.cheng@nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: April 18, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08522 Filed 4–20–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Health Services Organization, Delivery, Quality and Effectiveness.

Date: May 4, 2022.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Wenjuan Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480–8667, wangw2@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 15, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08500 Filed 4–20–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Biodata Management and Analysis Study Section.

Date: June 2–3, 2022.

Time: 9:00 a.m. to 8:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: E. Bryan Crenshaw, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–7129, bryan.crenshaw@nih.gov.

Name of Committee: Risk, Prevention and Health Behavior Integrated Review Group; Psychosocial Development, Risk and Prevention Study Section.

Date: June 2–3, 2022.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Anna L. Riley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301–435–2889 rileyann@csr.nih.gov.

Name of Committee: Cell Biology Integrated Review Group; Biology and Development of the Eye Study Section.

Date: June 2–3, 2022.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kevin Czaplinski, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–9139, czaplinskik2@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 15, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08501 Filed 4–20–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: NIDCR Special Grants Review Committee.

Date: June 23–24, 2022.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Dental & Craniofacial Research, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Nisan Bhattacharyya, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health, 6701 Democracy Boulevard, Suite 668, Bethesda, MD 20892, 301–451–2405, nisan.bhattacharyya@nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: April 18, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08521 Filed 4–20–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on June 21st, 2022, from 10:00 a.m. EDT to 4:30 p.m. EDT, and June 22nd, 2022, from 10:00 a.m. EDT to 1:00 p.m. EDT.

The board will meet in open-session June 21st, 2022, from 10:00 a.m. EDT to 2:15 p.m. EDT to discuss the Mandatory Guidelines for Federal Workplace Drug Testing Programs, updates on the Drug Free Workplace Program as well as updates from the Department of Transportation, the Nuclear Regulatory Commission, a presentation by Dr. Barry Sample on Workforce Drug Testing for Marijuana in 2021, and a presentation by Dr. Svante Vikingsson on Hydroxy Cocaine and Cocaine Ratios in Hair.

The board will meet in closed-session on June 21st, 2022, from 2:45 p.m. EDT to 4:30 p.m. EDT and June 22nd, 2022, from 10:00 a.m. EDT to 1:00 p.m. EDT, to discuss confidential issues surrounding the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair), preliminary and unpublished studies on hydroxy cocaine and cocaine ratios in hair, studies on quantitative agreement in hair labs, and oral fluid topical solution data from the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU). Therefore, the June 21st, 2022, from 2:45 to 4:30 and June 22nd, 2022, from 10:00 a.m. EDT to 1:00 p.m. EDT meetings are closed to the public, as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).

Meeting registration information can be completed at <http://snacregister.samhsa.gov/MeetingList.aspx>. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, <https://www.samhsa.gov/about-us/advisory-councils/meetings> or by contacting the Designated Federal Officer, Lisa Davis.